Recruiting PHASE2 Uterine Fibroid

New treatment option for Uterine Fibroid

Official title Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE

ClinicalTrials.gov ID: NCT06705075

What this study is testing

What is Perfluten?

Perfluten is an investigational medicine, being studied as a potential treatment for uterine fibroid.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 and older, women only

You may be able to join if

  • Be a female diagnosed with endometrial cancer and scheduled for UAE.
  • Be over the age of 18 years.
  • If the subject is of child-bearing potential, must have a negative pregnancy test.
  • Be conscious and able to comply with study procedures.
  • Have read and signed the IRB approved consent form for participating in the study.

You likely can't join if

  • Females who are pregnant or nursing.
  • Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards.
  • Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
  • Patients on life support or in a critical care unit.
  • Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.
  • Patients with recent cerebral hemorrhage.
See the full eligibility criteria
Who can join
  • Be a female diagnosed with endometrial cancer and scheduled for UAE.
  • Be over the age of 18 years.
  • If the subject is of child-bearing potential, must have a negative pregnancy test.
  • Be conscious and able to comply with study procedures.
  • Have read and signed the IRB approved consent form for participating in the study.
What rules you out
  • Females who are pregnant or nursing.
  • Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards.
  • Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:
  • Patients on life support or in a critical care unit.
  • Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia.
  • Patients with recent cerebral hemorrhage.
  • Patients who have undergone surgery within 24 hours prior to the study sonographic examination.
  • Patients with congenital heart defects.
  • Patient with a known allergy to Definity.

The study team makes the final eligibility decision.

Where it's taking place

  • Philadelphia, Pennsylvania, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.